Navigating Contradictions: Insights from 2025 Q1 Earnings Call on Product Strategy, Operating Expenses, and Revenue Growth

None



Amazfit Revenue Growth:
- Amazfit reported a 10% year-over-year growth in revenue for Q1 2025, marking the first year-over-year growth after two years of transformation.
- This growth is attributed to successful new product launches such as the Amazfit Active 2 and Bip 6, which have gained market share and positive consumer reception.

Supply Chain Diversification:
- Zepp Health Corporation diversified its supply chain, shifting most U.S.-bound production from China to Vietnam, which reduced exposure to China tariffs.
- This strategy was implemented to mitigate risks and optimize costs, ensuring operational agility amidst uncertain macroeconomic conditions and tariff policies.

Investment in R&D and New Product Development:
- The company increased R&D expenses by 3.4% year-over-year, with an emphasis on investing in new technologies and open-source AI to secure long-term technology leadership.
- This investment is aimed at driving product innovation and enhancing competitive positioning in the smart wearable market.

Gross Margin Expansion and Cost Management:
- Zepp Health achieved a gross margin of 37.3% in Q1 2025, a notable improvement over Q4 2024 and Q1 2024, driven by new product launches.
- The company remains committed to cost management, with a target to maintain operating expenses between $25 million to $27 million per quarter, focusing on operational efficiencies and supply chain diversity.